[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rhinosinusitis-acute\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rhinosinusitis-acute":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100622428","rhinavevaluation-of-treatments-for-acute-viral-rhinitis-rhinosinusitis-and-rhinopharyngitis-100622428",false,"NCT07383493","RhinAV_Evaluation of Treatments for Acute Viral Rhinitis, Rhinosinusitis, and Rhinopharyngitis","Evaluation of Treatments for Acute Viral Rhinitis, Rhinosinusitis, and Rhinopharyngitis","RhinAV","Inclusion Criteria:\n\n* Acute viral rhinitis or acute rhinosinusitis or viral rhinopharyngitis (sneezing, rhinorrhea, nasal obstruction, cough secondary to posterior rhinorrhea, sore throat) that began less than 72 hours prior to the inclusion visit, in the investigator's judgment,\n* Effective contraception for female patients of childbearing age.\n* Cooperation and sufficient understanding to comply with the requirements of the trial.\n* Acceptance of registration in the SI-RIPH VRB file.\n* Having received informed information and agreeing to give written consent.\n* Affiliated with the French Social Security system.\n\nExclusion Criteria:\n\n* Hypersensitivity\u002Fhistory of allergy to any of the product's components,\n* Complicated rhinitis, rhinosinusitis, or rhinopharyngitis (acute bacterial sinusitis, acute otitis media, acute bronchitis, or pneumonia) or severe cough that is poorly tolerated,\n* Chronic rhinosinusitis,\n* Allergic rhinosinusitis,\n* Other ongoing treatments for acute rhinitis (local treatment, antitussives, antibiotics, antiretrovirals, corticosteroids, etc.),\n* Positive antigen test for influenza A\u002FB or COVID-19 and infection requiring etiological treatment according to the recommendations,\n* Bacterial rhinopharyngitis with positive TROD test\n* Comorbidities or health conditions deemed incompatible with the trial by the investigator,\n* Recent ENT surgery (\\\u003C6 months),\n* ENT pathology such as nasal septum deviation or other causes of nasal obstruction,\n* Pulmonary pathology (COPD, asthma, etc.),\n* Immunosuppression (as reported by the patient),\n* Pregnant or breastfeeding women,\n* Currently participating in another clinical trial, or in the exclusion period, or having received total compensation of more than €6,000 in the 12 months prior to the start of the trial,\n* Benefiting from legal protection measures (guardianship, trusteeship, deprivation of liberty, judicial protection).","ALL","18 Years","70 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"NA","The objective of this study is to conduct post-marketing clinical follow-up of four products: NS, NHE, NHG, and PIR. This follow-up will consist of collecting clinical data in real-life conditions to confirm the tolerance, safety, and efficacy of medical devices used in the treatment of acute viral rhinitis, rhinosinusitis, and rhinopharyngitis, while also assessing the benefit\u002Frisk ratio of the products.",[28,29,30,31,32,33],"Rhinitis Acute","Rhinitis Viral","Rhinosinusitis Acute","Rhinopharyngitis","Rhinitis","Rhinosinusitis","RECRUITING","2026-06-12",{"date":37,"type":38},"2026-06-15","ACTUAL",{"date":40,"type":38},"2026-02-25",{"date":42,"type":22},"2027-03",{"name":44,"class":45},"University Hospital, Clermont-Ferrand","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100585356","phase-3-the-efficacy-and-safety-of-raphamin-in-the-treatment-of-acute-rhinosinusitis-in-adult-patients-100585356","NCT06901297","The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients","Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients","Inclusion Criteria:\n\n1. Male and female aged 18 - 75 years.\n2. Diagnosis of acute rhinosinusitis:\n\n   * 8-12 points on MSS scale;\n   * no more than 3 severe symptoms (3 points on the MSS scale)\n   * facial pain\u002Fheaviness in the facial area 1-2 points on the MSS scale.\n3. Disease duration up to 48 hours (from the onset of the first symptoms of the disease).\n4. Availability of a patient information sheet and an informed consent form for participation in the clinical trial signed by the patient.\n5. Patients who agreed to use a reliable method of contraception during the study (for men and women of reproductive potential).\n\nExclusion Criteria:\n\n1. Symptoms of acute bacterial rhinosinusitis (three or more of those below):\n\n   * fever of ≥ 38.0°C;\n   * the second wave of ARS symptoms;\n   * one-sided process;\n   * facial pain\u002Fpressure of 3 points (on the MSS scale).\n2. Recurrent ARS (≥4 episodes of ARS per year with complete resolution of symptoms between episodes).\n3. Odontogenic rhinosinusitis.\n4. Allergic (seasonal or year-round) rhinitis.\n5. Nasal polyps or clinically significant nasal septum deviation.\n6. Concomitant otitis.\n7. Use of intranasal or systemic corticosteroids for 30 days prior to the screening visit.\n8. Use of intranasal or systemic antibiotics for 30 days prior to the screening visit.\n9. Surgery for the nasal cavity and paranasal sinuses during the last 6 months before the screening visit.\n10. Any other surgery during the last 3 months.\n11. Clinical symptoms of severe influenza\u002FARVI requiring hospitalization.\n12. Suspected bacterial infection of any localization requiring the administration of antibiotics from the first day of disease.\n13. History\u002Fsuspicion of oncology of any localization (except for benign neoplasms).\n14. Exacerbation or decompensation of chronic diseases (diabetes mellitus, bronchial asthma, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, primary ciliary dyskinesia, bronchopulmonary dysplasia, malformations of the respiratory and ENT organs, etc.) affecting the patient's ability to participate in the clinical trial.\n15. Previously diagnosed immunodeficiency of any etiology.\n16. Unstable angina or myocardial infarction during the last 6 months.\n17. Class III and IV chronic heart failure (according to the classification of the New York Heart Association, 1964).\n18. History of chronic kidney disease (classes C3-5 A3).\n19. History of liver failure (class C according to Child-Pugh).\n20. Malabsorption syndrome, including congenital or acquired lactase or other disaccharidase deficiency, galactosemia.\n21. Pregnancy, breast-feeding, and childbirth less than 3 months before inclusion in the trial.\n22. Hypersensitivity to any component of the medicines used in the treatment.\n23. Patients who used medications listed under \"Prohibited Concomitant Treatment\" within 1 month prior to inclusion in the trial or need medications prohibited for use in the trial.\n24. Patients who, from the investigator's point of view, will not comply with the observation requirements during the trial or follow the procedure for taking the test drugs.\n25. History of mental illness, alcoholism, drug abuse, which, from the investigator's point of view, will prevent the patient from following the trial procedures.\n26. Participation in other clinical trials within 3 months prior to inclusion in this trial.\n27. Patient is related to on-site research personnel directly involved in the trial, or is the immediate family member of the investigator. 'Immediate family members' mean spouses, parents, children, or siblings, whether related or adopted.\n28. Patient is employed by OOO \"NPF \"MATERIA MEDICA HOLDING\", i.e., is an employee of the company, a temporary contract employee, or a designated official responsible for conducting the trial or their immediate family member.","75 Years",{"count":56,"type":22},552,[58],"PHASE3","Multicenter double-blind placebo-controlled randomized in parallel groups clinical trial of the efficacy and safety of Raphamin in the treatment of acute rhinosinusitis in adult patients.",[33,30],[33,62],"Acute","2026-03-12",{"date":65,"type":38},"2026-03-16",{"date":67,"type":38},"2025-04-03",{"date":69,"type":22},"2027-12-31",{"name":71,"class":72},"Materia Medica Holding","INDUSTRY",44]